Biochemical and Biological Characterization of Tumor-Associated Mutations of p110α

Methods in Enzymology

Volumn 438, Issue , 2008, Pages 291-305

  Denley, Adam ^a   Gymnopoulos, Marco ^a   Hart, Jonathan R ^a   Jiang, Hao ^a   Zhao, Li ^a   Vogt, Peter K ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ONCOPROTEIN; P110 ALPHA; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN P110; RAPAMYCIN; RHEB PROTEIN; UNCLASSIFIED DRUG; 1 PHOSPHATIDYLINOSITOL 3 KINASE P110 SUBUNIT, MOUSE; 1-PHOSPHATIDYLINOSITOL 3-KINASE P110 SUBUNIT, MOUSE; MONOMERIC GUANINE NUCLEOTIDE BINDING PROTEIN; NEUROPEPTIDE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE; PHOSPHATIDYLINOSITOL 3,4,5-TRIPHOSPHATE; POLYPHOSPHOINOSITIDE; RHEB PROTEIN, MOUSE;

BIOLOGICAL TRAIT; BLADDER CANCER; CARCINOGENICITY; CELL CULTURE; CELL MEMBRANE; CHEMICAL ANALYSIS; CHRONIC MYELOID LEUKEMIA; COLON CANCER; ENZYME ACTIVITY; GLIOBLASTOMA; HUMAN; MUTATION; NONHUMAN; PRIORITY JOURNAL; REVIEW; ANIMAL; ARTICLE; CELL TRANSFORMATION; GENETICS; MOUSE; NEOPLASM; PATHOPHYSIOLOGY; PHYSIOLOGY; SIGNAL TRANSDUCTION;

MURINAE; RATTUS;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; MICE; MONOMERIC GTP-BINDING PROTEINS; NEOPLASMS; NEUROPEPTIDES; PHOSPHATIDYLINOSITOL PHOSPHATES; SIGNAL TRANSDUCTION;

EID: 45549101613     PISSN: 00766879     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0076-6879(07)38020-8     Document Type: Review

References (78)

1. Andjelkovic M., et al. Role of translocation in the activation and function of protein kinase B. J. Biol. Chem. 272 (1997) 31515-31524
2. Auger K.R., et al. PDGF-dependent tyrosine phosphorylation stimulates production of novel polyphosphoinositides in intact cells. Cell 57 (1989) 167-175
3. Bachman K.E., et al. The PIK3CA gene is mutated with high frequency in human breast cancers. Cancer Biol. Ther. 3 (2004) 772-775
4. Bader A.G., et al. Oncogenic PI3K deregulates transcription and translation. Nat. Rev. 5 (2005) 921-929
5. Bader A.G., et al. Cancer-specific mutations in PIK3CA are oncogenic in vivo. Proc. Natl. Acad. Sci. USA 103 (2006) 1475-1479
6. Bellacosa A., et al. Akt activation by growth factors is a multiple-step process: The role of the PH domain. Oncogene 17 (1998) 313-325
7. Benistant C., et al. A specific function for phosphatidylinositol 3-kinase alpha (p85alpha-p110alpha) in cell survival and for phosphatidylinositol 3-kinase beta (p85alpha-p110beta) in de novo DNA synthesis of human colon carcinoma cells. Oncogene 19 (2000) 5083-5090
8. Bondeva T., et al. Bifurcation of lipid and protein kinase signals of PI3Kgamma to the protein kinases PKB and MAPK. Science 282 (1998) 293-296
9. Brader S., and Eccles S.A. Phosphoinositide 3-kinase signalling pathways in tumor progression, invasion and angiogenesis. Tumori 90 (2004) 2-8
10. Broderick D.K., et al. Mutations of PIK3CA in anaplastic oligodendrogliomas, high-grade astrocytomas, and medulloblastomas. Cancer Res. 64 (2004) 5048-5050
11. Casey P.J., et al. p21ras is modified by a farnesyl isoprenoid. Proc. Natl. Acad. Sci. USA 86 (1989) 8323-8327
12. Castro A.F., et al. Rheb binds tuberous sclerosis complex 2 (TSC2) and promotes S6 kinase activation in a rapamycin- and farnesylation-dependent manner. J. Biol. Chem. 278 (2003) 32493-32496
13. Chan T.O., et al. Small GTPases and tyrosine kinases coregulate a molecular switch in the phosphoinositide 3-kinase regulatory subunit. Cancer Cell 1 (2002) 181-191
14. Clark G.J., et al. The Ras-related protein Rheb is farnesylated and antagonizes Ras signaling and transformation. J. Biol. Chem. 272 (1997) 10608-10615
15. Damen J.E., et al. The 145-kDa protein induced to associate with Shc by multiple cytokines is an inositol tetraphosphate and phosphatidylinositol 3,4,5-triphosphate 5-phosphatase. Proc. Natl. Acad. Sci. USA 93 (1996) 1689-1693
16. Denley A., et al. Oncogenic signaling of class I PI3K isoforms. Oncogene (2007)
17. Downward J. PI 3-kinase, Akt and cell survival. Semin. Cell Dev. Biol. 15 (2004) 177-182
18. Fan Q.W., et al. A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma. Cancer Cell 9 (2006) 341-349
19. Forbes S., et al. COSMIC 2005. Br. J. Cancer 94 (2006) 318-322
20. Foukas L.C., et al. Critical role for the p110alpha phosphoinositide-3-OH kinase in growth and metabolic regulation. Nature 441 (2006) 366-370
21. Frattini M., et al. Phosphatase protein homologue to tensin expression and phosphatidylinositol-3 phosphate kinase mutations in colorectal cancer. Cancer Res. 65 (2005) 112-127
22. Garami A., et al. Insulin activation of Rheb, a mediator of mTOR/S6K/4E-BP signaling, is inhibited by TSC 1 and 2. Mol. Cell 11 (2003) 1457-1466
23. Guertin D.A., et al. Ablation in mice of the mTORC components raptor, rictor, or mLST8 reveals that mTORC2 is required for signaling to Akt-FOXO and PKCalpha, but not S6K1. Dev. Cell 11 (2006) 859-871
24. Gymnopoulos M., et al. Rare cancer-specific mutations in PIK3CA show gain of function. Proc. Natl. Acad. Sci. USA 104 (2007) 5569 4474
25. Hara K., et al. 1-Phosphatidylinositol 3-kinase activity is required for insulin-stimulated glucose transport but not for RAS activation in CHO cells. Proc. Natl. Acad. Sci. USA 91 (1994) 7415-7419
26. Hawkins P.T., et al. Signalling through class I PI3Ks in mammalian cells. Biochem. Soc. Trans. 34 (2006) 647-662
27. Hickey F.B., and Cotter T.G. BCR-ABL regulates phosphatidylinositol 3-kinase-p110gamma transcription and activation and is required for proliferation and drug resistance. J. Biol. Chem. 281 (2006) 2441-2450 (Epub 2005 Nov 16.)
28. Hooshmand-Rad R., et al. The PI 3-kinase isoforms p110(alpha) and p110(beta) have differential roles in PDGF- and insulin-mediated signaling. J. Cell Sci. 113 Pt 2 (2000) 207-214
29. Ikenoue T., et al. Functional analysis of PIK3CA gene mutations in human colorectal cancer. Cancer Res. 65 (2005) 4562-4567
30. Inoki K., et al. Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling. Genes Dev. 17 (2003) 1829-1834
31. Isakoff S.J., et al. Breast cancer-associated PIK3CA mutations are oncogenic in mammary epithelial cells. Cancer Res. 65 (2005) 10992-11000
32. Kang S., et al. Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic. Proc. Natl. Acad. Sci. USA 102 (2005) 802-807 (Epub 2005 Jan 12.)
33. Kang S., et al. Mutated PI 3-kinases: Cancer targets on a silver platter. Cell Cycle 4 (2005) 578-581
34. Kang S., et al. Oncogenic transformation induced by the p11 Obeta, -gamma, and -delta isoforms of class I phosphoinositide 3-kinase. Proc. Natl. Acad. Sci. USA 103 (2006) 1289-1294
35. Knobbe C.B., et al. Genetic alteration and expression of the phosphoinositol-3-kinase/Akt pathway genes PIK3CA and PIKE in human glioblastomas. Neuropathol. Appl. Neurobiol. 31 (2005) 486-490
36. Li J., et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 275 (1997) 1943-1947
37. Li J., et al. Modulation of insulin receptor substrate-1 tyrosine phosphorylation by an AkUphosphatidylinositol 3-kinase pathway. J. Biol. Chem. 274 (1999) 9351-9356
38. Liaw D., et al. Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nat. Genet. 16 (1997) 64-67
39. Lioubin M.N., et al. p150Ship, a signal transduction molecule with inositol polyphosphate-5-phosphatase activity. Genes Dev. 10 (1996) 1084-1095
40. Long X., et al. Rheb binds and regulates the mTOR kinase. Curr. Biol. 15 (2005) 702-713
41. Maehama T., and Dixon J.E. The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J. Biol. Chem. 273 (1998) 13375-13378
42. Mizoguchi M., et al. Genetic alterations of phosphoinositide 3-kinase subunit genes in human glioblastomas. Brain Pathol. (Zurich) 14 (2004) 372-377
43. Nimnual A.S., et al. Coupling of Ras and Rac guanosine triphosphatases through the Ras exchanger Sos. Science 279 (1998) 560-563
44. Oda K., et al. High frequency of coexistent mutations of PIK3CA and PTEN genes in endometrial carcinoma. Cancer Res. 65 (2005) 10669-10673
45. Okkenhaug K., et al. Impaired B and T cell antigen receptor signaling in p110delta PI 3-kinase mutant mice. Science 297 (2002) 1031-1034
46. Ooms L.M., et al. The inositol polyphosphate 5-phosphatase, PIPP, is a novel regulator of phosphoinositide 3-kinase-dependent neurite elongation. Mol. Biol. Cell 17 (2006) 607-622 (Epub 2005 Nov 9.)
47. Pacold M.E., et al. Crystal structure and functional analysis of Ras binding to its effector phosphoinositide 3-kinase gamma. Cell 103 (2000) 931-943
48. Parsons R. Human cancer, PTEN and the PI-3 kinase pathway. Semin. Cell Dev. Biol. 15 (2004) 171-176
49. Parsons R., and Simpson L. PTEN and cancer. Methods Mol. Biol. 222 (2003) 147-166
50. Repasky G.A., et al. Renewing the conspiracy theory debate: Does Raf function alone to mediate Ras oncogenesis?. Trends Cell Biol. 14 (2004) 639-647
51. Rodriguez-Viciana P., et al. Activation of phosphoinositide 3-kinase by interaction with Ras and by point mutation. EMBO J. 15 (1996) 2442-2451
52. Rodriguez-Viciana P., et al. Signaling specificity by Ras family GTPases is determined by the full spectrum of effectors they regulate. Mol. Cell Biol. 24 (2004) 4943-4954
53. Samuels Y., and Ericson K. Oncogenic PI3K and its role in cancer. Curr. Opin. Oncol. 18 (2006) 77-82
54. Samuels Y., and Velculescu V.E. Oncogenic mutations of PIK3CA in human cancers. Cell Cycle 3 (2004) 1221-1224
55. Samuels Y., et al. High frequency of mutations of the PIK3CA gene in human cancers. Science 304 (2004) 554
56. Sarbassov D.D., et al. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol. Cell 22 (2006) 159-168
57. Sasaki T., et al. Function of PI3Kgamma in thymocyte development, T cell activation, and neutrophil migration. Science 287 (2000) 1040-1046
58. Saucedo L.J., et al. Rheb promotes cell growth as a component of the insulin/TOR signalling network. Nat. Cell Biol. 5 (2003) 566-571
59. Schonleben F., et al. PIK3CA mutations in intraductal papillary mucinous neoplasm/carcinoma of the pancreas. Clin. Cancer Res. 12 (2006) 3851-3855
60. Skorski T., et al. Transformation of hematopoietic cells by BCR/ABL requires activation of a PI-3k/Akt-dependent pathway. EMBO J. 16 (1997) 6151-6161
61. Steck P.A., et al. Identification of a candidate tumour suppressor gene, MMAC 1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat. Genet. 15 (1997) 356-362
62. Stephens L., et al. Phosphoinositide 3-kinases as drug targets in cancer. Curr. Opin. Pharmacol. 5 (2005) 357-365
63. Stocker H., et al. Rheb is an essential regulator of S6K in controlling cell growth in Drosophila. Nat. Cell Biol. 5 (2003) 559-565
64. Suire S., et al. Activation of phosphoinositide 3-kinase gamma by Ras. Curr. Biol. 12 (2002) 1068-1075
65. Sujobert P., et al. Essential role for the p110delta isoform in phosphoinositide 3-kinase activation and cell proliferation in acute myeloid leukemia. Blood 106 (2005) 1063-1066 (Epub 2005 Apr 19.)
66. Tee A.R., et al. Tuberous sclerosis complex gene products, Tuberin and Hamartin, control mTOR signaling by acting as a GTPase-activating protein complex toward Rheb. Curr. Biol. 13 (2003) 1259-1268
67. Thomas R.K., et al. High-throughput oncogene mutation profiling in human cancer. Nat. Genet 39 (2007) 347-351 (Epub 2007 Feb 11.)
68. Urano J., et al. The Saccharomyces cerevisiae Rheb G-protein is involved in regulating canavanine resistance and arginine uptake. J. Biol. Chem. 275 (2000) 11198-11206
69. Vanhaesebroeck B., and Waterfield M.D. Signaling by distinct classes of phosphoinositide 3-kinases. Exp. Cell Res. 253 (1999) 239-254
70. Vanhaesebroeck B., et al. Phosphoinositide 3-kinases: A conserved family of signal transducers. Trends Biochem. Sci. 22 (1997) 267-272
71. Vanhaesebroeck B., et al. Distinct PI(3)Ks mediate mitogenic signalling and cell migration in macro phages. Nat. Cell Biol. 1 (1999) 69-71
72. Walker E.H., et al. Structural insights into phosphoinositide 3-kinase catalysis and signalling. Nature 402 (1999) 313-320
73. Wang Y., et al. PIK3CA mutations in advanced ovarian carcinomas. Hum. Mutat. 25 (2005) 322
74. Watton S.J., and Downward J. AktlPKB localisation and 3′ phosphoinositide generation at sites of epithelial cell-matrix and cell-cell interaction. Curr. Biol. 9 (1999) 433-436
75. Yang W., et al. Failure to farnesylate Rheb protein contributes to the enrichment of GO/G1 phase cells in the Schizosaccharomyces pombe farnesyltransferase mutant. Mol. Microbiol. 41 (2001) 1339-1347
76. Zhang Y., et al. Rheb is a direct target of the tuberous sclerosis tumour suppressor proteins. Nat. Cell Biol. 5 (2003) 578-581
77. Zhao J.J., et al. The oncogenic properties of mutant p110alpha and p110beta phosphatidylinositol 3-kinases in human mammary epithelial cells. Proc. Natl. Acad. Sci. USA 102 (2005) 18443-18448
78. Zhao L., and Vogt P.K. Helical domain and kinase domain mutations in p110a of phosphatidylinositol 3-kinase induce gain of function by different mechanisms. Proc. Natl. Acad. Sci. USA (2008) (in press)